All In Biotech

Drug Trial Radar · NCT05368974

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

An Observational Study of Mother-Infant Outcomes Following Antenatal Exposure to Direct-Acting Antivirals: the Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 11, 2022

Primary completion

Jun 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
The Task Force for Global HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centers for Disease Control and Prevention
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now recommended in many countries, there is no approved treatment for HCV during pregnancy. An observational study is here proposed to assess outcomes of mother-infant pairs exposed to DAAs during pregnancy within a global clinical case registry. Data regarding the exposures and outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited and collected from clinical providers, healthcare facilities, HCV treatment programs, and other clinical practices worldwide. Data will be shared and maintained within a secure database, and cumulative data will be analyzed at pre-determined six-month intervals. The primary outcome will be the number and proportion of mother-infant pairs with adverse pregnancy or birth outcomes. The results of this study will inform HCV treatment decisions by clinical providers and programs worldwide.

Conditions

  • Hepatitis C

Interventions

  • Direct Acting AntiviralsDrug

    Direct-acting antiviral exposure during documented pregnancy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse pregnancy outcomesTime frame: 1 year
  2. Number of adverse birth outcomesTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Taskforce for Global Health

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.